CDEX Completes Shipment of 10 ValiMed CCT Systems Ahead of Schedule

CDEX Completes Shipment of 10 ValiMed CCT Systems Ahead of Schedule 
TUCSON, AZ -- (Marketwire) -- 03/25/13 --  CDEX Inc. (OTCQB: CDEX), a
leading developer of chemical detection products using patented
technologies for use in healthcare, safety and security markets,
today announced the company completed and shipped the 10 unit order
of its ValiMed(TM) CCT drug validation system to Al-Essa Medical &
Scientific Equipment Company in Safat, Kuwait ahead of schedule. The
shipment completes the sale secured in December of 2012. The units
will be placed in service at medical facilities throughout the region
along with testing supplies for initial operation. Each unit placed
requires additional service for installation and ongoing product
support by CDEX for two years from the date of delivery. 
"The on time completion and delivery of the 10 CCT units is a
demonstration of our team's ability to execute timely. The future
sales of supplies and service related to the initial transaction of
these units will further our recurring sales and service revenue. The
Al-Essa Group will utilize the ValiMed systems to underpin their
client's efforts help assure the highest patient safety and to fight
narcotics diversion in the healthcare systems they serve," stated
Jeff Brumfield, chairman and chief executive officer of CDEX. "Our
agreement with Al-Essa Group provides CDEX Inc. access to markets in
the Middle East and could be a key foothold to build our
international reach in the Middle East for our Valimed technology. We
intend to showcase the Valimed G4 system to their customers once
final testing is completed and the contracted units are shipped to
U.S. customers during the second quarter this year." 
CDEX was contracted to deliver the 10 ValiMed CCT units in the first
quarter of 2013 and receive final payment balance of the order within
thirty days of shipment. The company will provide the initial
training and support to Al-Essa's technical staff and the Al-Essa
trainers and service personnel will then take full responsibilities
for installation and training for their clients once both parties are
satisfied with the aptitude and proficiency. 
The ValiMed(TM) Medication Validation and Narcotics Return System
(Model CCT), is a lightweight, compact table top instrument that can
be
 used in virtually any clinical environment where high-risk IV
medications are compounded before being dispensed to the patient, or
where narcotics are returned after being dispensed. CDEX's ValiMed
drug validation technology helps healthcare providers ensure patient
safety and control costs by reducing medication errors and mitigating
drug diversion. The patented & patent pending detection process
identifies drugs in real-time, validating medication and treatment
solutions authenticity and specificity.  
About Al-Essa Group
 For over 30 years, professionals in healthcare,
analytical and various other industries have experienced Al-Essa's
proven commitment to deliver total solutions to clients in both
private and public institutions, in Kuwait and GCC. With a long and
proven experience in introducing cutting-edge healthcare and
analytical equipment from world-class manufacturers, their activities
range from supplying products, supporting applications and providing
maintenance for medical and analytical needs, address human resource
requirements through supplemental staffing and home healthcare
programs, and deliver complete solutions in facility engineering. To
date, Al-Essa has executed several projects on a turnkey basis by
combining local project management and project support expertise with
international technology partners. For more information visit
www.alessakuwait.com  
About CDEX Inc.
 CDEX develops, manufactures and globally distributes
products to the healthcare, safety and security markets. The
ValiMed(TM) product line provides life-saving validation of high-risk
medications and pharmacy returned narcotics. The ID2(TM) product line
detects trace amounts of illegal drugs, such as methamphetamine. CDEX
expects to advance its patented technologies to serve additional
markets in the future where its proprietary products can be launched.
To learn more about CDEX please visit: www.cdex-inc.com. 
Safe Harbor Statement
 Non-historical statements are forward-looking,
as defined in federal securities laws, and generally can be
identified by words such as "expects," "plans," "may," "believes,"
"should," "intends," and similar words. These statements pose risks
that cannot be accurately predicted. Consequently, results may differ
materially from those expressed or implied. Such risks and
uncertainties include, without limitation, the effectiveness,
profitability and marketability of products, the protection of
intellectual property and proprietary information, and other risks
detailed periodically in filings with the SEC. There is no obligation
to update any forward-looking statements. 
Company contact:
Jeff Brumfield
Chairman and CEO
1-520-745-5172 
investorrelations@cdex-inc.com 
 
 
Press spacebar to pause and continue. Press esc to stop.